The investment was made to support UPL’s acquisition of US-based Arysta LifeScience (Arysta) for $4.2 billion, creating a global market leader in post-patent agricultural chemicals, with proforma revenues of over $4 billion and pre-tax earnings of over $1 billion.
The combined business brought together UPL’s strong manufacturing capabilities and well-diversified product portfolio, with Arysta’s asset-light business model, strong research and development capabilities, and exposure to fast-growing niche products.
Furthermore the combined business expects to benefit from significant cost and revenue synergies given its complementary product portfolio and geographic exposure.
ADIA’s Private Equities team was already familiar with the Arysta business and the strategy of its parent company, Platform Specialty Products. This knowledge contributed to UPL developing a compelling investment proposal, which positioned UPL as the most logical buyer of the business.
The structure of the deal ultimately enabled UPL to complete a transformative transaction.
